Related Experiment Video
Updated: Aug 3, 2026
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients
D Hinze-Selch1, E W Becker, G M Stein
1Max Planck Institute of Psychiatry, Clinical Institute, Munich, Germany.
Insights
Clozapine treatment impacts immune cells, suppressing their activity in vivo. However, adding clozapine directly to cell cultures boosts immune cell proliferation and cytokine release, showing distinct effects.
Area of Science:
- Immunology
- Pharmacology
- Neuroscience
Background:
- Clozapine, an atypical antipsychotic, possesses immunomodulatory properties.
- Understanding clozapine's effects on the immune system is crucial for patient management.
- Previous research suggests clozapine influences immune cell function.
Purpose of the Study:
- To investigate the in vitro immune parameter changes in peripheral blood mononuclear cells (PBMC) during clozapine treatment.
- To determine the differential effects of in vivo clozapine treatment versus in vitro clozapine addition on PBMC.
- To assess alterations in PBMC proliferation, cytokine secretion, serum autoantibodies, and immunoglobulin levels.
Main Methods:
- Studied 17 patients undergoing clozapine treatment over the first 6 weeks.
- Measured PBMC proliferation and cytokine secretion (IL-6, sIL-2r).
- Assessed serum autoantibodies and immunoglobulin (IgG) levels.
Main Results:
- In vivo clozapine treatment suppressed PBMC proliferation and soluble interleukin-2 receptor (sIL-2r) shedding.
- In vitro clozapine addition stimulated PBMC proliferation and secretion of IL-6 and sIL-2r.
- Serum IgG levels increased, while autoantibody patterns remained unchanged.
Conclusions:
- Clozapine treatment exerts distinct in vivo and in vitro effects on immune parameters.
- Immune modulation by clozapine occurs independently of dosage and body temperature.
- Further research is needed to elucidate the clinical implications of these differential immune effects.
Abstract:
Clozapine is an atypical antipsychotic agent with immunomodulatory properties. We hypothesized that in vitro immune parameters of peripheral blood mononuclear cells (PBMC) are affected in the course of clozapine treatment and that clozapine per se, added in vitro to PBMC cultures of clozapine-treated patients, exerts differential effects in the timecourse of treatment in vivo. We measured proliferation and cytokine secretion of PBMC, serum autoantibodies, and immunoglobulin levels in 17 patients before and during the first 6 weeks of clozapine treatment. Independent of clozapine dosage and rectal temperature, clozapine treatment in vivo suppressed proliferation and shedding of sIL-2r by PBMC, and the addition of clozapine in vitro induced, relative to unstimulated conditions, PBMC proliferation and secretion of IL-6 and sIL-2r. Serum IgG levels were increased; whereas, autoantibody pattern was unaffected. Thus, clozapine treatment and the addition of clozapine in vitro exert differential effects on various in vitro immune parameters independent of clozapine dosage and rectal temperature in the course of treatment.
